India, April 18 -- President Donald Trump signed an executive order on Saturday aimed at enhancing research into psychedelic ibogaine to facilitate its use in treating PTSD among veterans and traumatic brain injuries.

The new order from Trump instructs the Food and Drug Administration (FDA) to take new actions regarding drug safety regulation. The agency is expected to provide updated guidance to researchers on how to structure clinical trials for substances such as psilocybin, ibogaine, and other serotonin receptor agonists. These substances, which also encompass LSD and MDMA, are known to induce hallucinogenic effects and are prohibited in the United States.

The POTUS emphasized the potential benefits of these drugs for military veter...